Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * SHANNON COLIN	2. Issuer Name and Ticker or Trading Symbol PRA Health Sciences, Inc. [ PRAH ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) President & CEO
(Last)          (First)          (Middle) C/O PRA HEALTH SCIENCES, INC., 4130 PARKLAKE AVENUE, SUITE 400	3. Date of Earliest Transaction (MM/DD/YYYY) 6/17/2021
(Street) RALEIGH, NC 27612 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	6/17/2021		M		77425	A	$11.73	132051	D
Common Stock	6/17/2021		M		166036	A	$11.73	298087	D
Common Stock	6/17/2021		M		91000	A	$75.81	389087	D
Common Stock	6/17/2021		M		31000	A	$95.94	420087	D
Common Stock	6/17/2021		M		45000	A	$102.44	465087	D
Common Stock	6/17/2021		M		31780	A	$103.30	496867	D
Common Stock	6/17/2021		S(1)		920	D	$166.89 (2)	495947	D
Common Stock	6/17/2021		S(1)		161352	D	$168.13 (3)	334595	D
Common Stock	6/17/2021		S(1)		220195	D	$169.00 (4)	114400	D
Common Stock	6/17/2021		S(1)		59774	D	$169.63 (5)	54626	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.73	6/17/2021		M			77425	11/16/2016	12/20/2023	Common Stock	77425	$0	0	D
Stock Option (Right to Buy)	$11.73	6/17/2021		M			166036	(6)	12/20/2023	Common Stock	166036	$0	0	D
Stock Option (Right to Buy)	$75.81	6/17/2021		M			91000	(7)	8/29/2027	Common Stock	91000	$0	39000	D
Stock Option (Right to Buy)	$95.94	6/17/2021		M			31000	(8)	8/13/2029	Common Stock	31000	$0	62000	D
Stock Option (Right to Buy)	$102.44	6/17/2021		M			45000	(9)	8/16/2028	Common Stock	45000	$0	45000	D
Stock Option (Right to Buy)	$103.30	6/17/2021		M			31780	(10)	6/1/2030	Common Stock	31780	$0	63560	D

Explanation of Responses:
(1)	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
(2)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $166.43 to $167.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2), (3), (4) and (5) of this Form 4.
(3)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $167.53 to $168.525, inclusive.
(4)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $168.53 to $169.52, inclusive.
(5)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $169.53 to $169.87, inclusive.
(6)	The option vested in five equal annual installments, commencing on September 23, 2014
(7)	The option vests in four annual installments, commencing on August 29, 2018 at 20% of the grant in the first two years and 30% of the grant in the remaining two years thereafter.
(8)	The option vests in three equal annual installments of 31,000 beginning on August 13, 2020.
(9)	The option vests in four equal annual installments of 22,500 beginning on August 16, 2019.
(10)	The option vests in three equal annual installments of 31,780 beginning on June 1, 2021.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
SHANNON COLIN C/O PRA HEALTH SCIENCES, INC. 4130 PARKLAKE AVENUE, SUITE 400 RALEIGH, NC 27612	X		President & CEO

Signatures
By: /s/ Christopher L. Gaenzle, by power of attorney		6/21/2021
**Signature of Reporting Person		Date